New pill shows promise against tough prostate cancer
NCT ID NCT01171898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male hormones that fuel cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARN-509 (apalutamide), a drug that blocks male hormones that fuel prostate cancer growth
What this could lead to
If successful, this could lead to a new oral treatment option for men with advanced prostate cancer that no longer responds to standard hormone therapy.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe in larger studies. Side effects and limited benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
San Diego, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Baltimore, Maryland, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Omaha, Nebraska, United States
-
Study site
New York, New York, United States
-
Study site
Raleigh, North Carolina, United States
-
Study site
Portland, Oregon, United States
-
Study site
Lancaster, Pennsylvania, United States
-
Study site
Myrtle Beach, South Carolina, United States
-
Study site
Dallas, Texas, United States
-
Study site
Seattle, Washington, United States
-
Study site
Madison, Wisconsin, United States